NOTCH3 and breast cancer: Because we identified a novel cross-talk between AURKA and NOTCH3 oncogenic pathways in promoting breast cancer progression, we speculate that dual-targeted therapy with selective inhibitors of AURKA and NOTCH3 could also represent a novel stemness-targeted therapeutic strategy to successfully eradicate BT-MICs, particularly for the clinical management of highly aggressive TNBCs that currently lack effective U.S. Food and Drug Administration-approved targeted therapies.